Clinical trial · Observational
Focal Therapy for Localized Prostate Cancer
China Medical University Hospital, Taichung, Taiwan
NCT03970863CI-TRIAL-00073853withdrawnClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): difficulty in recruiting participants
Summary
Brief summary (as posted)
To evaluate the cancer control for prostate cancer patients treated with focal therapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Prostate Health Index | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- oncological outcome
- timeFrame
- 6 months
- description
- MR/US fusion prostate biopsy to see if there is recurrent cancer
- measure
- biochemical outcome
- timeFrame
- 1 month, 3 months, 6 months, 9 months, 12 months, 15 months, 18 months, 21 months, 24 months
- description
- change of Prostate Health Index (PSA, free PSA, and p2PSA will be combined to report PHI)
Secondary outcomes (5)
- measure
- Functional outcome
- timeFrame
- 1 month, 3 months, 6 months, 9 months, 12 months, 15 months, 18 months, 21 months, 24 months
- description
- change of Uroflowmetry, including maximal flow rate in milliliter per second and post-void residual volume in milliliter
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 40 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * biopsy-proven unilateral prostate cancer, the other side insignificant cancer (Gleason 6 or less and maximal cancer core length 4mm or less) is allowed * clinical T2a or less * Gleason 4+3 or less * serum PSA less than 20 ng/mL Exclusion Criteria: * T2b or higher * Gleason 4+4 or higher * serum PSA 20 or higher * lymph node or distant metastasis * previous treatment with prostatectomy, radiotherapy, androgen deprivation therapy, HIFU, or cryoablation
References
Publications (0)
Data not yet available
No reference posted for this study.